Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : World Outlook -- Ignore unavailable to you. Want to Upgrade?

To: betone who wrote (1038)	11/13/2002 10:46:57 PM
From: Julius Wong	Respond to of 49160

vaxgen.com * The only company with HIV/AIDS vaccine candidates in Phase III clinical trials * Two separate trials, involving nearly 8,000 volunteers on three continents, are testing two formulations of AIDSVAX * Primary results from the first of the two trials are expected to be available in the first quarter of 2003 * AIDSVAX has a strong safety profile and induces an immune response in nearly everyone who receives it * VaxGen is the largest shareholder in Celltrion, Inc., a joint venture that is building two facilities for the manufacture of AIDSVAX, if it is licensed, and other biopharmaceutical products